Diseases & Disorders
(G30Z)
990 on File
OHIO HEMATOPOIETIC TRANSPLANT AND CELLULAR THERAPY CONSORTIUM
Financial strength (30%)
83/100
Reliability (20%)
55/100
Effectiveness (25%)
65/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2025
$157K
Total Revenue
$100K
Total Expenses
$259K
Net Assets
0
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
92.4%
Fundraising Efficiency
N/A
Operating Reserve
31.14x
Liability-to-Asset
27.8%
Revenue Diversification
100.0%
Compared with Peers
FY 2025
Compared with 783 similar organizations
(United States, Diseases & Disorders, under $100K in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
92.4% | 79.3% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
7.6% | 6.9% |
P10P90
|
Below median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
0.0% | 0.0% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
31.1 mo | 20.6 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
27.8% | 0.0% |
P10P90
|
Bottom quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
100.0% | 99.4% |
P10P90
|
Below median |
|
Surplus margin
Surplus as a share of revenue
|
36.6% | 12.9% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $157K | $100K | $259K | 92.4% | 0 |
| 2023 | $99K | $131K | $218K | 94.0% | 0 |
| 2022 | $105K | $83K | $220K | 91.5% | 0 |
| 2021 | $79K | $72K | N/A | — | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.